Alkem Laboratories profit and loss

Latest FY26

Revenue: ₹14,712cr+13.5% on FY25
EBITDA: ₹3,005cr+19.6% on FY25
Net profit: ₹2,351cr+6.1% on FY25
EPS: ₹192.51+6.3% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	15,081	14,712	12,965	12,668	11,599	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	600	583	494	311	216
	15,681	15,296	13,458	12,978	11,815
	3,648	3,565	3,440	3,295	3,057
	1,663	1,695	1,514	1,629	1,388
	−189	−167	−190	14.1	462
	2,953	2,837	2,454	2,201	2,131
	178	161	122	112	107
	395	382	357	299	310
	3,973	3,777	3,234	3,284	2,952
	12,621	12,250	10,931	10,834	10,408
	3,032	3,005	2,512	2,245	1,609
	2,638	2,623	2,155	1,946	1,299
Profit
	3,060	3,046	2,527	2,145	1,408
	−188	−175	0.0	−121	−103
	2,872	2,871	2,527	2,023	1,305
	711	620	524	422	274
	−45.0	−102	−213	−211	24.1
	666	518	311	212	298
	−2.1	−2.0	−0.6	0.0	0.0
	2,204	2,351	2,215	1,811	1,007
	2,206	2,353	2,216	1,811	1,007
	185	184	19.7	20.0	115
	2,389	2,535	2,235	1,832	1,122
	2,158	2,302	2,165	1,796	984
	46.7	49.4	49.9	15.7	22.6
Per share
	₹180.44	₹192.51	₹181.11	₹150.19	₹82.31
	₹180.44	₹192.51	₹181.11	₹150.19	₹82.31
Other comprehensive income — detail
	185	184	19.7	—	—
	14.3	12.1	−21.8	−9.3	−4.9
	3.3	3.8	−7.2	−3.0	—
	—	—	—	−3.0	−1.6
	174	176	34.3	26.4	118
	2,340	2,484	2,186	1,816	1,099
	48.4	50.8	48.9	15.1	22.2
Per share — as-filed variants
	₹180.44	₹192.51	₹181.11	₹150.19	₹82.31
	₹180.44	₹192.51	₹181.11	₹150.19	₹82.31
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	9,958	9,620	8,200	7,730	6,692
	66.0%	65.4%	63.3%	61.0%	57.7%
Adjusted (ex-exceptional items) — derived
	3,060	3,046	2,527	2,145	1,408
	−188	−175	0.0	−121	−103
	2,348	2,494	2,215	1,920	1,086
	₹192.25	₹204.24	₹181.11	₹159.21	₹88.81

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ALKEM₹5,079.00

Alkem Laboratories Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersMANKIND TORNTPHARM IPCALAB LUPIN FORTIS AUROPHARMA LAURUSLABS BIOCONMcap ₹60,719 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	11,599.3	12,667.6	12,964.5	14,712.3	15,081.3
Other Income	216.1	310.8	493.7	583.4	599.6
Total Income	11,815.3	12,978.4	13,458.3	15,295.6	15,680.9
Expenses
+ Cost of Materials Consumed	3,056.9	3,294.6	3,440.4	3,565.4	3,648.3
+ Purchases of Stock-in-Trade	1,387.6	1,628.9	1,514.0	1,694.5	1,663.3
+ Changes in Inventories	462.4	14.1	-190.1	-167.1	-188.7
+ Employee Benefit Expense	2,131.4	2,201.0	2,453.9	2,837.1	2,952.8
+ Finance Costs	107.4	112.4	121.7	160.8	177.6
+ Depreciation & Amortisation	310.4	299.3	357.2	382.1	394.6
+ Other Expenses	2,951.6	3,283.5	3,234.2	3,777.2	3,973.4
Total Expenses	10,407.6	10,833.8	10,931.2	12,249.9	12,621.3
EBITDA	1,609.5	2,245.5	2,512.2	3,005.2	3,032.2
EBIT	1,299.0	1,946.2	2,155.0	2,623.2	2,637.6
Profit
PBT before Exceptional Items	1,407.8	2,144.6	2,527.0	3,045.7	3,059.6
+ Exceptional Items	-103.0	-121.5	0.0	-174.8	-187.8
Pretax Income	1,304.8	2,023.1	2,527.0	2,870.9	2,871.9
+ Current Tax	273.9	422.3	523.6	619.7	710.6
+ Deferred Tax	24.1	-210.6	-212.6	-101.9	-45.0
Tax Expense	298.0	211.7	311.0	517.8	665.6
+ Share of Associates & JVs	0.0	0.0	-0.6	-2.0	-2.1
Net Income	1,006.8	1,811.5	2,215.4	2,351.2	2,204.2
+ Net Income — Continuing Ops	1,006.8	1,811.5	2,216.0	2,353.1	2,206.3
+ Other Comprehensive Income	114.9	20.0	19.7	183.8	184.6
Total Comprehensive Income	1,121.7	1,831.5	2,235.1	2,535.0	2,388.8
Net Income to Common	984.2	1,795.8	2,165.5	2,301.8	2,157.5
Minority Interest	22.6	15.7	49.9	49.4	46.7
Per Share
Basic EPS	82.31	150.19	181.11	192.51	180.44
Diluted EPS	82.31	150.19	181.11	192.51	180.44
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	19.7	183.8	184.6
+ Items NOT to be Reclassified to P&L	-4.9	-9.3	-21.8	12.1	14.3
+ Tax on Items NOT to be Reclassified	—	-3.0	-7.2	3.8	3.3
+ Tax on Items NOT to be Reclassified — alt tag	-1.6	-3.0	—	—	—
+ Items to be Reclassified to P&L	118.2	26.4	34.3	175.5	173.5
Comprehensive Income — Owners of Parent	1,099.5	1,816.4	2,186.2	2,484.2	2,340.5
Comprehensive Income — Non-controlling Interests	22.2	15.1	48.9	50.8	48.4
Per Share — as-filed variants
Basic EPS — Continuing Operations	82.31	150.19	181.11	192.51	180.44
Diluted EPS — Continuing Operations	82.31	150.19	181.11	192.51	180.44
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	6,692.4	7,730.0	8,200.3	9,619.5	9,958.4
Gross Margin %	57.70	61.02	63.25	65.38	66.03
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	1,407.8	2,144.6	2,527.0	3,045.7	3,059.6
− Exceptional Items (reconciliation)	-103.0	-121.5	0.0	-174.8	-187.8
Net Income Adj (tax-effected)	1,086.3	1,920.2	2,215.4	2,494.5	2,348.5
EPS Adj	88.81	159.21	181.11	204.24	192.25
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	23.9	23.9	23.9	23.9	23.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.